In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone

Xenobiotica

Volumn 32, Issue 11, 2002, Pages 949-962

  Yan, Z ^a   Caldwell, G W ^a   Wu, W N ^a   McKown, L A ^a   Rafferty, B ^a   Jones, W ^a   Masucci, J A ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; ETHER DERIVATIVE; ETOPERIDONE; KETOCONAZOLE; LIVER ENZYME; PIPERAZINE DERIVATIVE; RECOMBINANT ENZYME; RWJ 26872; TRIAZOLE DERIVATIVE; COMPLEMENTARY DNA; DRUG DERIVATIVE; ISOPROTEIN; RECOMBINANT PROTEIN; STEROID HORMONE 6 BETA HYDROXYLASE; STEROID HORMONE 6-BETA-HYDROXYLASE; STEROID MONOOXYGENASE; TRAZODONE;

ARTICLE; DEALKYLATION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME; CHEMICAL MODEL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; KINETICS; LIQUID CHROMATOGRAPHY; LIVER; MASS SPECTROMETRY; METABOLISM;

CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; LIVER; MASS SPECTROMETRY; MICROSOMES, LIVER; MODELS, CHEMICAL; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; STEROID HYDROXYLASES; TRAZODONE;

EID: 0036850028     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250210163298     Document Type: Article

References (34)

1. Atkins, W. M., Wang, R. W. and Lu, A. Y. H., 2001, Allosteric behavior in cytochrome P450-dependent in vitro drug-drug interactions: A prospective based on conformational dynamics. Chemical Research in Toxicology, 14, 338-347.
2. Baldwin, S. J., Bloomer, J. C., Smith, G, J, Ayrton A. D., Clarke, S. E., Catanese, B., Barillari, G. and Galli Angeli, D., 1982, Studies on the oral absorption in man of etoperidone tablets and capsules. Bollettino Chimica Farmaceutico, 121, 530-534.
3. 14C] etoperidone in man. Xenobiotica, 31, 823-839.
4. Chang, T. K. H., Gonzalez, F. J. and Waxman, D. J., 1994, Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311, 437-442.
5. Chenery, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261-270.
6. Domanski, T. L., He, Y. A., Khan, K. K., Roussel, F., Wang, Q. and Halpert, J. R., 2001, Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry, 40, 10150-10160.
7. Eagling, V. A., Tjia, J. F. and Back, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107-114.
8. Fong, M. H., Garattini, S. and Caccia, S., 1982, 1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone, and mepiprazole. Journal of Pharmaceutics and Pharmacology, 34, 674-675.
9. Hyland, R., Roe, E. G. H., Jones, B. C. and Smith, D. A., 2001, Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. British Journal of Clinical Pharmacology, 51, 239-248.
10. Lin, J. H. and Lu, A. H. Y., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics, 35, 361-390.
11. Maenpaa, J., Hall, S. D., Ring, B. J., Strom, S. C. and Wrighton, S. A., 1998, Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone. Pharmacogenetics, 8, 137-155.
12. Maes, M., Westenberg, H., Vandoolaeghe, E., Demedts, P., Wauters, A., Neels, H. and Meltzer, H. Y., 1997, Effects of trazodone and fluoxetine in the treatment of major depression: Therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. Journal of Clinical Psychopharmacology, 17, 358-364.
13. Mancy, A., Dijols, S., Poli, S., Guengerich, P. and Mansuy, D., 1996, Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specifc inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry, 35, 16205-16212.
14. Newton, D. J., Wang, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
15. Ngui, J. S., Chen, Q., Shou, M., Wang, R. W., Stearns, R. A., Baillie, T. A. and Tang, W., 2001, In vitro stimulation of warfarin metabolism by quinidine: Increases in the formation of 4- and 10hydroxywarfarin. Drug Metabolism and Disposition, 29, 877-886.
16. Ngui, J. S., Tang, W., Stearns, R. A., Shou, M., Miller, R. R., Zhang, Y., Lin, J. H. and Baillie, T. A., 2000, Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metabolism and Disposition, 28, 1043-1050.
17. Ono, S., Hatanaka, T., Hotta, H., Satoh, T., Gonzalez, F. J. and Tsutsui, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681-693.
18. Otton, S. V., Crewe, H. K., Lennard, M. S., Tucker, G. T. and Woods, H. F., 1988, Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 247, 242-247.
19. Prakash, C., Kamel, A., Cui, D., Whalen, R. D., Miceli, J. J. and Tweedie, D., 2000, Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. British Journal of Clinical Pharmacology, 49 (suppl. 1), 35S-42S.
20. Przegalinski, E. and Lewandowska, A., 1979, The effect of etoperidone a new potential antidepressant drug, on the central serotonin system. Journal of Neural Transmission, 46, 303-312.
21. Raffa, R. B., Shank, R. P. and Vaught, J. L. 1992, Etoperidone, trazodone and MCPP: In vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity. Psychopharmacology, 108, 320-326.
22. Rotzinger, S., Fang, J. and Baker, G. B., 1998, Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metabolism and Disposition, 26, 572-575.
23. Sai, Y., Dai, R., Yang, T. J., Krausz, K. W., Gonzalez, F. J., Gelboin, H. V. and Shou, M., 2000, Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica, 30, 327-343.
24. Shou, M., Grogan, J., Mancewicz, J. A., Krausz, K. W., Gonzalez, F. J., Gelboin, H. V. and Korzekwa, K. R., 1994, Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome p450 active site. Biochemistry, 33, 6450-6455.
25. Tang, W. and Stearns, R. A., 2001, Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Current Drug Metabolism, 2, 185-198.
26. Tassaneeyakul, W., Birkett, D. J., Veronese, M. E., McManus, M. E., Tukey, R. H., Quattrochi, L. C., Gelboin, H. V. and Miners, J. O., 1993, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401-407.
27. Von Moltke, L. L., Greenblatt, D. J., Granda, B. W., Grassi, J. M., Schmider, J., Harmatz, J. S. and Shader, R. I., 1999, Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: Cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology, 145, 113-122.
28. Wang, R. W., Newton, D. J., Liu, N., Atkins, W. M. and Lu, A. Y. H., 2000, Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metabolism and Disposition, 28, 360-366.
29. Wu, W. N., Caldwell, G. W. and Uetz, J. A., 1991, Biotransformation of etoperidone in man. Pharmacologist, 33, 208-212.
30. Wu, W. N., Masucci, J. A., McKown, L. A. and Rodgers, J. D., 1995, Identification of four plasma metabolites of etoperidone in dogs. Journal of Pharmaceutics and Biomedical Analysis, 13, 177-184.
31. Wu, W. N. and McKown, L. A., 2000, Recent advances in biotransformation of CNS and cardiovascular agents. Current Drug Metabolism, 1, 255-270.
32. Wu, W. N. and McKown, L. A., 2001, In vitro metabolism of etoperidone in human hepatic S9 fraction. Drug Metabolism Reviews, 33, 123.
33. Zalma, A., von Moltke, L. L., Granda, B. W., Harmatz, J. S., Shader, R. I. and Greenblatt, D. J., 2000, In vitro metabolism of trazodone by CYP3A: Inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biology and Psychiatry, 47, 655-661.
34. Zhou, S., Paxton, J. W., Tingle, M. D. and Kestell, P., 2000, Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metabolism and Disposition, 28, 1449-1456.